JP Patent

JP2019108362A — ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス

Assigned to Biodelivery Sciences International Inc · Expires 2019-07-04 · 7y expired

What this patent protects

【課題】ブプレノルフィンの送達のための乱用抑止粘膜付着性デバイスの提供。【解決手段】約4.0〜約6.0のpHに緩衝された有効量のブプレノルフィンを含む粘膜付着性層；および約4.0〜約4.8のpHに緩衝されたバッキング層を含む、デバイス。【選択図】図１

USPTO Abstract

【課題】ブプレノルフィンの送達のための乱用抑止粘膜付着性デバイスの提供。【解決手段】約4.0〜約6.0のpHに緩衝された有効量のブプレノルフィンを含む粘膜付着性層；および約4.0〜約4.8のpHに緩衝されたバッキング層を含む、デバイス。【選択図】図１

Drugs covered by this patent

Subutex (Buprenorphine Hydrochloride) · Indivior

Patent Metadata

Patent number: JP2019108362A
Jurisdiction: JP
Classification: —
Expires: 2019-07-04
Drug substance claim: No
Drug product claim: No
Assignee: Biodelivery Sciences International Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.